glutathione parkinsons study Potential use of as a treatment for Parkinson's disease The glutathione system in Parkinson's

To validate the methods feasibility, we selected the marketed covalent inhibitors afatinib (for lung cancer) and ibrutinib (for lymphoma) as test compounds, assessing their binding ability to GSH using this approach

L.PayneS

(2010) and Al-Dean and Hammoud (2024) reported that low concentrations of NAC improved motility parameters, while higher concentrations (2.5 and 5 mM) induced hyperactivated motility, potentially leading to premature acrosomal reaction and compromised fertility (Alahmar, 2019)

It prevents lipodystrophy, a condition where fat tissue at the injection site hardens, shrinks, or thickens due to repeated use

A study by Staresinic et al